US5399363A
(en)
*
|
1991-01-25 |
1995-03-21 |
Eastman Kodak Company |
Surface modified anticancer nanoparticles
|
US5429824A
(en)
*
|
1992-12-15 |
1995-07-04 |
Eastman Kodak Company |
Use of tyloxapole as a nanoparticle stabilizer and dispersant
|
US5518738A
(en)
*
|
1995-02-09 |
1996-05-21 |
Nanosystem L.L.C. |
Nanoparticulate nsaid compositions
|
US5591456A
(en)
*
|
1995-02-10 |
1997-01-07 |
Nanosystems L.L.C. |
Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
|
US5834025A
(en)
*
|
1995-09-29 |
1998-11-10 |
Nanosystems L.L.C. |
Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
|
WO1998035666A1
(en)
*
|
1997-02-13 |
1998-08-20 |
Nanosystems Llc |
Formulations of nanoparticle naproxen tablets
|
US6045829A
(en)
*
|
1997-02-13 |
2000-04-04 |
Elan Pharma International Limited |
Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
|
CA2273272C
(en)
*
|
1997-10-07 |
2004-09-21 |
Fuisz Technologies Ltd. |
Immediate release drug delivery forms
|
US6013280A
(en)
*
|
1997-10-07 |
2000-01-11 |
Fuisz Technologies Ltd. |
Immediate release dosage forms containing microspheres
|
IE980115A1
(en)
*
|
1998-02-16 |
2000-02-09 |
Biovail Internat Ltd |
Solubilizing delivery systems and method of manufacture
|
EP2266542A3
(de)
*
|
1998-10-01 |
2013-07-31 |
Elan Pharma International Limited |
Nanopartikelformulierungen mit kontrollierter Wirkstofffreisetzung
|
US8236352B2
(en)
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
UA74539C2
(en)
|
1999-12-08 |
2006-01-16 |
Pharmacia Corp |
Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
|
US6316029B1
(en)
*
|
2000-05-18 |
2001-11-13 |
Flak Pharma International, Ltd. |
Rapidly disintegrating solid oral dosage form
|
AR035642A1
(es)
|
2000-05-26 |
2004-06-23 |
Pharmacia Corp |
Uso de una composicion de celecoxib para el alivio rapido del dolor
|
US20050048126A1
(en)
|
2000-12-22 |
2005-03-03 |
Barrett Rabinow |
Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
|
US8067032B2
(en)
|
2000-12-22 |
2011-11-29 |
Baxter International Inc. |
Method for preparing submicron particles of antineoplastic agents
|
US9700866B2
(en)
|
2000-12-22 |
2017-07-11 |
Baxter International Inc. |
Surfactant systems for delivery of organic compounds
|
EP1429772A1
(de)
|
2001-09-25 |
2004-06-23 |
Pharmacia Corporation |
N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazol
|
US20060003012A9
(en)
|
2001-09-26 |
2006-01-05 |
Sean Brynjelsen |
Preparation of submicron solid particle suspensions by sonication of multiphase systems
|
EP1429749A2
(de)
|
2001-09-26 |
2004-06-23 |
Baxter International Inc. |
Herstellung von nanopartikeln im submikrometerbereich durch dispersion und entzug des lösungsmittels oder der flüssigen phase
|
US9101540B2
(en)
|
2002-04-12 |
2015-08-11 |
Alkermes Pharma Ireland Limited |
Nanoparticulate megestrol formulations
|
EP1531799A1
(de)
*
|
2002-06-10 |
2005-05-25 |
Elan Pharma International Limited |
Pharmazeutische nanopartikel-formulierungen mit hmg-coa-reduktase-inhibitoren ("statine"), neue kombinationen davon sowie herstellung dieser pharmazeutischen zusammensetzungen
|
UY27939A1
(es)
|
2002-08-21 |
2004-03-31 |
Glaxo Group Ltd |
Compuestos
|
ES2365012T3
(es)
*
|
2002-11-12 |
2011-09-20 |
Elan Pharma International Limited |
Formas farmacéuticas sólidas de desintegración rápida que no son friables y que comprenden pululano.
|
EP1938803A3
(de)
*
|
2003-03-03 |
2010-10-27 |
Elan Pharma International Limited |
Formulierungen mit Nanoteilchen-Meloxican
|
US20100297252A1
(en)
|
2003-03-03 |
2010-11-25 |
Elan Pharma International Ltd. |
Nanoparticulate meloxicam formulations
|
US8512727B2
(en)
*
|
2003-03-03 |
2013-08-20 |
Alkermes Pharma Ireland Limited |
Nanoparticulate meloxicam formulations
|
GB0418791D0
(en)
*
|
2004-08-23 |
2004-09-22 |
Glaxo Group Ltd |
Novel process
|
US9149433B2
(en)
*
|
2004-11-30 |
2015-10-06 |
Basf Corporation |
Method for formation of micro-prilled polymers
|
JP2008545808A
(ja)
*
|
2005-05-23 |
2008-12-18 |
エラン・ファルマ・インターナショナル・リミテッド |
血小板凝集阻害薬を含むナノ粒子状および制御放出組成物
|
CL2007002689A1
(es)
|
2006-09-18 |
2008-04-18 |
Vitae Pharmaceuticals Inc |
Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
|
US8426467B2
(en)
|
2007-05-22 |
2013-04-23 |
Baxter International Inc. |
Colored esmolol concentrate
|
US8722736B2
(en)
|
2007-05-22 |
2014-05-13 |
Baxter International Inc. |
Multi-dose concentrate esmolol with benzyl alcohol
|
EP2172193A1
(de)
|
2008-10-02 |
2010-04-07 |
Capsulution Nanoscience AG |
Verbesserte Nanopartikel-Zusammensetzungen schlecht löslicher Verbindungen
|
US7828996B1
(en)
|
2009-03-27 |
2010-11-09 |
Abbott Cardiovascular Systems Inc. |
Method for the manufacture of stable, nano-sized particles
|
AR077692A1
(es)
|
2009-08-06 |
2011-09-14 |
Vitae Pharmaceuticals Inc |
Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
|
JP5499703B2
(ja)
*
|
2009-12-28 |
2014-05-21 |
ライオン株式会社 |
イブプロフェン含有製剤
|
JP6166721B2
(ja)
|
2011-07-22 |
2017-07-19 |
ケモセントリックス, インコーポレイテッド |
4−tert−ブチル−N−[4−クロロ−2−(1−オキシ−ピリジン−4−カルボニル)−フェニル]−ベンゼンスルホンアミドのナトリウム塩の多形
|
WO2013016174A1
(en)
|
2011-07-22 |
2013-01-31 |
Chemocentryx, Inc. |
A crystalline form of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide
|
CN103906744A
(zh)
|
2011-09-01 |
2014-07-02 |
葛兰素集团有限公司 |
新晶型
|
KR101794032B1
(ko)
*
|
2011-09-21 |
2017-11-07 |
(주)바이오시네틱스 |
나노입자 제조방법
|
US9393202B2
(en)
*
|
2013-04-26 |
2016-07-19 |
Chiesi Farmaceutici S.P.A |
Particle size reduction of an antimuscarinic compound
|
CR20160598A
(es)
|
2014-06-25 |
2017-03-10 |
Glaxosmithkline Intelectual Property Dev Ltd |
Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il) amino)-n-(3-(3,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil) pirimidino-4-carboxamida
|
JP2017527574A
(ja)
|
2014-09-08 |
2017-09-21 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
2−(4−(4−エトキシ−6−オキソ−1,6−ジヒドロピリジン−3−イル)−2−フルオロフェニル)−n−(5−(1,1,1−トリフルオロ−2−メチルプロパン−2−イル)イソオキサゾール−3−イル)アセトアミドの結晶形
|
WO2016086950A1
(en)
|
2014-12-03 |
2016-06-09 |
Rontis Hellas S.A. |
Pharmaceutical composition containing non-lipophilic hydrophobic drug and process for the preparation thereof
|
CN107001810A
(zh)
|
2014-12-15 |
2017-08-01 |
M技术株式会社 |
有机物微粒的制造方法及有机物微粒的改性方法
|
EP3528792A1
(de)
|
2016-10-20 |
2019-08-28 |
Dukebox SP. Z O.O. |
Verfahren zur herstellung einer lösung aus nsaid-nanopartikeln
|
JPWO2020179701A1
(de)
|
2019-03-01 |
2020-09-10 |
|
|
US20220287985A1
(en)
|
2019-08-16 |
2022-09-15 |
Hiroshima Metal & Machinery Co., Ltd |
Organic nanoparticle production method and organic nanoparticles
|